Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0000078003 XXXXXXXX LIVE 13 Ordinary Shares, nominal value GBP0.01 per share 02/25/2025 false 0001900304 405552100 Haleon plc Building 5, First Floor, The Heights Weybridge, Surrey X0 KT13 0NY Margaret M. Madden, Esq. 212-733-2323 Pfizer Inc. 66 Hudson Boulevard East New York NY 10001 Jacob A. Kling, Esq. 212-403-1000 Wachtell, Lipton, Rosen & Katz 51 West 52nd Street New York NY 10019 0000078003 N Pfizer Inc. OO N DE 661709764.00 0.00 661709764.00 0.00 661709764.00 N 7.3 CO 661,709,764 Ordinary Shares includes: (1) 661,709,764 Ordinary Shares, nominal value GBP0.01 per share ("Ordinary Shares"), of Haleon plc (the "Issuer"), held on behalf of Pfizer Inc. ("Pfizer" or the "Reporting Person") by Pfizer's nominee and (2) zero American Depositary Shares. See Item 5. Percent of class represented by amount in row (11) is calculated based upon 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on February 3, 2025. The CUSIP on the cover page applies to the Issuer's American Depositary Shares, each representing two Ordinary Shares. No CUSIP has been assigned to the Ordinary Shares. Ordinary Shares, nominal value GBP0.01 per share Haleon plc Building 5, First Floor, The Heights Weybridge, Surrey X0 KT13 0NY Explanatory Note The following constitutes Amendment No. 13 ("Amendment No. 13") to the Schedule 13D filed with the SEC by Pfizer on July 27, 2022, as amended by Amendment No. 1 on February 1, 2023, Amendment No. 2 on May 15, 2023, Amendment No. 3 on September 11, 2023, Amendment No. 4 on October 10, 2023, Amendment No. 5 on January 19, 2024, Amendment No. 6 on March 19, 2024, Amendment No. 7 on March 22, 2024, Amendment No. 8 on July 29, 2024, Amendment No. 9 on October 1, 2024, Amendment No. 10 on October 3, 2024, Amendment No. 11 on January 16, 2025 and Amendment No. 12 on January 21, 2025 (the "Schedule 13D"). This Amendment No. 13 amends and supplements the Schedule 13D as specifically set forth herein. Except as set forth herein, the Schedule 13D is unmodified. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. Item 4 of the Schedule 13D is hereby supplemented as follows: As previously disclosed, the Pfizer Relationship Agreement terminated following the closing of the January 2025 Secondary Offering and Pfizer no longer has the contractual right to nominate representative directors to be appointed to the Board. As a result, Mr. Supran stepped down from the Board on February 25, 2025. The first and second paragraphs of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs: On February 25, 2025, Pfizer withdrew the Ordinary Shares underlying the restricted American Depositary Shares that it previously held under a restricted American Depositary Receipts facility with JPMorgan Chase Bank, N.A., as depositary. The number of Ordinary Shares beneficially owned by Pfizer remains unchanged as a result of such withdrawal. As of the date of this Schedule 13D, Pfizer is the beneficial owner of 661,709,764 Ordinary Shares, which represents approximately 7.3% of the Issuer's outstanding Ordinary Shares. Pfizer's beneficial ownership is composed of (1) 661,709,764 Ordinary Shares held on behalf of Pfizer by Pfizer's nominee and (2) zero American Depositary Shares. The beneficial ownership percentage reported herein was calculated based on 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the SEC on February 3, 2025. The number of Ordinary Shares as to which the Reporting Person has the sole power to vote or direct the vote is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to vote or direct the vote is zero. The number of Ordinary Shares as to which the Reporting Person has the sole power to dispose or direct the disposition is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to dispose or direct the disposition is zero. See (a). No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. No amendment to this Item is being made. Pfizer Inc. /s/ Madelyn D. Purcell Madelyn D. Purcell/Assistant Secretary 02/27/2025